title: Short-term effects of low-calcium dialysis solutions on calcium mass transfer, ionized calcium, and parathyroid hormone in CAPD patients.
abstract: Patients on CAPD using calcium carbonate (CaCO3) as phosphate binder might benefit from low-calcium (Ca) concentration dialysis solutions; however, no data are available for the effects of this regimen on Ca metabolism. We studied 10 patients on stable CAPD regimens with standard dialysis solutions (Ca 7 mg/dL) who were taking CaCO3 to control hyperphosphatemia (mean daily doses 4.5 +/- 2.4 g). Hypercalcemic episodes had been recorded in 6 patients. Standard dialysis solutions were replaced with solutions containing 5 mg/dL of Ca. Calcium and phosphate peritoneal mass transfer (MT), serum concentrations of total Ca, ionized Ca (Ca++), phosphate, intact PTH, and mid-molecular PTH, were evaluated before and 48 hours after change of dialysate. The switch to low-Ca solutions was accompanied by significant changes in calcium mass transfer (Ca MT) (+9.84 +/- 48.22 versus -96.74 +/- 48.32 mg/day, p less than .001). Ca MT was significantly (p less than .05) correlated with the serum/dialysate Ca gradient. There was no difference in phosphate MT. Serum Ca++ significantly (p less than .05) decreased from 5.20 +/- 0.32 to 4.88 +/- 0.36 mg/dL, and intact PTH significantly increased (81.5 +/- 139 versus 112.4 +/- 168 pg/mL, p less than .05). It is concluded that dialysis solutions with Ca 5 mg/dL result in a negative peritoneal Ca MT and can be useful to prevent and treat hypercalcemia in CAPD patients taking CaCO3 as phosphate binder. A careful monitoring of ionized calcium, PTH, and phosphate is suggested when an extensive and long-term use of this solution is considered.
authors.affiliation: Department of Nephrology, Provincial Hospital, Sondrio, Italy.
authors.forename: B
authors.initials: B
authors.lastname: Pagliari
authors.forename: A
authors.initials: A
authors.lastname: Baretta
authors.forename: V
authors.initials: V
authors.lastname: De Cristofaro
authors.forename: F
authors.initials: F
authors.lastname: Samà
authors.forename: A
authors.initials: A
authors.lastname: Cantaluppi
authors.forename: L
authors.initials: L
authors.lastname: Martis
authors.forename: E
authors.initials: E
authors.lastname: Imbasciati
mesh_terms: D000328:Adult; D002118:Calcium / Q000008:administration & dosage / Q000032:analysis / Q000378:metabolism*; D015314:Dialysis Solutions / Q000032:analysis; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood*; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000379:methods; D010710:Phosphates / Q000378:metabolism; D012709:Serum Albumin; D013997:Time Factors
chemical_list: D015314:Dialysis Solutions; D010281:Parathyroid Hormone; D010710:Phosphates; D012709:Serum Albumin; D002118:Calcium